JP2013199488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013199488A5 JP2013199488A5 JP2013121984A JP2013121984A JP2013199488A5 JP 2013199488 A5 JP2013199488 A5 JP 2013199488A5 JP 2013121984 A JP2013121984 A JP 2013121984A JP 2013121984 A JP2013121984 A JP 2013121984A JP 2013199488 A5 JP2013199488 A5 JP 2013199488A5
- Authority
- JP
- Japan
- Prior art keywords
- tpr
- disintegrating tablet
- orally disintegrating
- beads
- tablet composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011324 bead Substances 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 22
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 22
- 229920000642 polymer Polymers 0.000 claims 18
- 239000008186 active pharmaceutical agent Substances 0.000 claims 17
- 239000011248 coating agent Substances 0.000 claims 14
- 238000000576 coating method Methods 0.000 claims 14
- 239000007962 solid dispersion Substances 0.000 claims 14
- 230000002708 enhancing effect Effects 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 9
- 239000002702 enteric coating Substances 0.000 claims 7
- 238000009505 enteric coating Methods 0.000 claims 7
- 229920001577 copolymer Polymers 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 229920003176 water-insoluble polymer Polymers 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims 2
- 229960004294 lercanidipine Drugs 0.000 claims 2
- 230000000873 masking effect Effects 0.000 claims 2
- -1 opioid agonists Substances 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229940127450 Opioid Agonists Drugs 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003120 clonazepam Drugs 0.000 claims 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000004503 fine granule Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940127227 gastrointestinal drug Drugs 0.000 claims 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229960003162 iloperidone Drugs 0.000 claims 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims 1
- 229960002497 nicorandil Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84189306P | 2006-08-31 | 2006-08-31 | |
| US84176006P | 2006-08-31 | 2006-08-31 | |
| US60/841,893 | 2006-08-31 | ||
| US60/841,760 | 2006-08-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526896A Division JP5513113B2 (ja) | 2006-08-31 | 2007-08-29 | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013199488A JP2013199488A (ja) | 2013-10-03 |
| JP2013199488A5 true JP2013199488A5 (enExample) | 2014-04-17 |
| JP5913207B2 JP5913207B2 (ja) | 2016-04-27 |
Family
ID=39136847
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526896A Expired - Fee Related JP5513113B2 (ja) | 2006-08-31 | 2007-08-29 | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
| JP2013121984A Active JP5913207B2 (ja) | 2006-08-31 | 2013-06-10 | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526896A Expired - Fee Related JP5513113B2 (ja) | 2006-08-31 | 2007-08-29 | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20080069878A1 (enExample) |
| EP (1) | EP2056792B1 (enExample) |
| JP (2) | JP5513113B2 (enExample) |
| KR (2) | KR101468053B1 (enExample) |
| BR (1) | BRPI0716196A2 (enExample) |
| CA (1) | CA2661683C (enExample) |
| ES (1) | ES2953390T3 (enExample) |
| IL (1) | IL197204A0 (enExample) |
| MX (2) | MX2009002166A (enExample) |
| NZ (1) | NZ575171A (enExample) |
| RU (1) | RU2434630C2 (enExample) |
| WO (1) | WO2008027993A2 (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| WO2006047493A2 (en) | 2004-10-21 | 2006-05-04 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
| NZ575171A (en) * | 2006-08-31 | 2012-04-27 | Aptalis Pharmatech Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
| CA2711475A1 (en) * | 2008-01-10 | 2009-07-16 | Evonik Roehm Gmbh | Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release |
| ES2715274T3 (es) * | 2008-01-10 | 2019-06-03 | Evonik Roehm Gmbh | Preparación farmacéutica o nutracéutica recubierta con liberación de sustancias activas mejorada |
| US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| FR2930147B1 (fr) * | 2008-04-18 | 2013-02-08 | Flamel Tech Sa | Forme orale solide dotee d'un double profil de liberation |
| MX2010011880A (es) * | 2008-04-29 | 2011-05-25 | Pharnext | Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular. |
| CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
| CA2722905C (en) * | 2008-05-08 | 2016-08-16 | Supernus Pharmaceuticals Inc. | Controlled release formulations of alprazolam |
| FR2938432B1 (fr) * | 2008-11-14 | 2011-05-20 | Debregeas Et Associes Pharma | Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus |
| KR101788804B1 (ko) * | 2008-11-18 | 2017-10-20 | 유씨비 파마, 에스.에이. | ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형 |
| KR101689688B1 (ko) * | 2008-11-18 | 2016-12-26 | 유씨비 파마, 에스.에이. | ２옥소１피롤리딘 유도체를 포함하는 지연 방출형 제형 |
| MX339136B (es) * | 2008-12-12 | 2016-05-13 | Rhein Siegfried Sa De Cv | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla. |
| JP5783908B2 (ja) | 2008-12-19 | 2015-09-24 | スパーナス ファーマシューティカルズ インコーポレイテッド | 攻撃性を治療する方法 |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| US20100159009A1 (en) * | 2008-12-24 | 2010-06-24 | Zhongshui Yu | Controlled-release formulations |
| KR101640164B1 (ko) * | 2009-01-29 | 2016-07-15 | 유씨비 파마, 에스.에이. | ２옥소１피롤리딘 유도체를 포함하는 약학적 조성물 |
| JP2012518655A (ja) * | 2009-02-23 | 2012-08-16 | アプタリス ファーマテック インコーポレイテッド | プロトンポンプ阻害剤を含む制御放出組成物 |
| US20110311626A1 (en) * | 2009-02-23 | 2011-12-22 | Gopi Venkatesh | Controlled release compositions comprising anti-cholinergic drugs |
| WO2010118232A1 (en) * | 2009-04-09 | 2010-10-14 | Elan Pharma International Limited | Controlled-release clozapine compositions |
| JP5758899B2 (ja) * | 2009-09-17 | 2015-08-05 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 活性物質を含有するコーティングにより被覆されたペレット |
| FR2951378B1 (fr) * | 2009-10-16 | 2012-06-01 | Flamel Tech Sa | Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee |
| MX337603B (es) | 2009-11-30 | 2016-03-10 | Adare Pharmaceuticals Inc | Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion. |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| EP2515863A2 (en) | 2009-12-23 | 2012-10-31 | Lupin Limited | Slow release pharmaceutical compositions of iloperidone |
| CN102106807B (zh) * | 2009-12-29 | 2013-03-27 | 上海中西制药有限公司 | 一种固体制剂的制备方法及所得固体制剂 |
| WO2011082426A1 (en) * | 2010-01-04 | 2011-07-07 | Eurand, Inc. | Controlled release compositions comprising meclizine or related piperazine derivatives |
| AR079862A1 (es) * | 2010-01-08 | 2012-02-22 | Eurand Inc | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion |
| DE102010005124A1 (de) * | 2010-01-19 | 2012-03-01 | Stada Arzneimittel Ag | Feste pharmazeutische Zusammensetzung umfassend Lercanidipin |
| EP3572074B1 (en) * | 2010-03-31 | 2021-01-06 | Supernus Pharmaceuticals, Inc. | Stabilized formulations of molindone |
| EP2563339A1 (en) * | 2010-04-29 | 2013-03-06 | Lupin Limited | Controlled release pharmaceutical compositions of brivaracetam |
| AU2011256928A1 (en) * | 2010-05-24 | 2012-12-20 | Lupin Limited | Extended release formulation of pramipexole |
| CA2804504C (en) * | 2010-07-09 | 2018-08-21 | Teijin Pharma Limited | Intraorally disintegrating tablet |
| US9011912B2 (en) | 2010-10-07 | 2015-04-21 | Abon Pharmaceuticals, Llc | Extended-release oral dosage forms for poorly soluble amine drugs |
| CN102440971A (zh) * | 2010-10-15 | 2012-05-09 | 重庆市力扬医药开发有限公司 | 伊潘立酮口腔崩解片 |
| NZ611467A (en) | 2010-12-02 | 2015-06-26 | Aptalis Pharmatech Inc | Rapidly dispersing granules, orally disintegrating tablets and methods |
| CN102614140B (zh) * | 2011-01-26 | 2015-11-25 | 浙江九洲药物科技有限公司 | 伊潘立酮口崩片及其制备方法 |
| WO2012123963A2 (en) * | 2011-02-24 | 2012-09-20 | Megafine Pharma (P) Ltd. | A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient |
| DE102011051308A1 (de) * | 2011-06-24 | 2012-12-27 | Hennig Arzneimittel Gmbh & Co. Kg | Herstellungsverfahren und Arzneiform |
| KR20140057604A (ko) | 2011-08-12 | 2014-05-13 | 베링거잉겔하임베트메디카게엠베하 | 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제 |
| EP2604256B1 (en) * | 2011-12-14 | 2016-04-13 | Hexal AG | Multi layer coatings |
| EP2704689B1 (en) * | 2012-04-19 | 2018-11-28 | Glatt AG | Taste-masked pharmaceutical compositions containing diclofenac |
| DK2898886T3 (en) * | 2012-09-19 | 2017-03-27 | Taiho Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED ELUTION AND / OR ABSORPTION |
| US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| US9597339B2 (en) | 2013-02-01 | 2017-03-21 | Glialogix, Inc. | Compositions and methods for the treatment of neurodegenerative and other diseases |
| WO2014144512A1 (en) | 2013-03-15 | 2014-09-18 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2938699A1 (en) | 2014-02-05 | 2015-08-13 | Kashiv Pharma Llc | Abuse-resistant drug formulations with built-in overdose protection |
| WO2015141662A1 (ja) * | 2014-03-18 | 2015-09-24 | 武田薬品工業株式会社 | 固体分散体 |
| JP6510628B2 (ja) | 2014-03-26 | 2019-05-15 | サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド | 乱用防止即時放出性被覆リザーバ固体剤形 |
| JP2017528431A (ja) * | 2014-07-17 | 2017-09-28 | ジェローム シェンターク， | 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| US11395808B2 (en) | 2016-04-08 | 2022-07-26 | Cereno Scientific Ab | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| WO2018055615A1 (en) * | 2016-09-22 | 2018-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Injectable implants |
| WO2018156585A1 (en) * | 2017-02-21 | 2018-08-30 | Ico Therapeutics Inc. | Solid oral formulations of amphotericin b |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| CA3129056A1 (en) * | 2018-02-21 | 2019-08-29 | Aron H. BLAESI | Expanding structured dosage form |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| WO2020061308A1 (en) * | 2018-09-21 | 2020-03-26 | Kashiv Biosciences, Llc | Extended release compositions comprising trihexyphenidyl |
| US20210393588A1 (en) * | 2018-11-02 | 2021-12-23 | Zenvision Pharma Llp | Ready to use intravenous infusion of brivaracetam or salt thereof |
| US10679018B1 (en) | 2019-02-05 | 2020-06-09 | International Business Machines Corporation | Magnetic tracking for medicine management |
| US10824822B2 (en) * | 2019-02-05 | 2020-11-03 | International Business Machines Corporation | Magnetic tracking for medicine management |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021231792A1 (en) * | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CN113350309B (zh) * | 2021-08-09 | 2021-11-12 | 北京五和博澳药业股份有限公司 | 一种难溶性药物渗透泵控释片剂及其制备方法 |
| US11648207B1 (en) * | 2021-12-15 | 2023-05-16 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of Clozapine |
| US12303604B1 (en) * | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
| WO1991006291A1 (fr) * | 1989-10-26 | 1991-05-16 | Nippon Shinyaku Co., Ltd. | Preparation a liberation entretenue |
| JP4072597B2 (ja) * | 1994-12-27 | 2008-04-09 | ナムローゼ・フェンノートシャップ・オルガノン | 持続性製剤 |
| JPH08208476A (ja) * | 1995-02-01 | 1996-08-13 | Kanebo Ltd | ニフェジピン含有持続性製剤 |
| PT914818E (pt) | 1996-06-14 | 2005-08-31 | Kyowa Hakko Kogyo Kk | Comprimido de desintegracao rapida por via intraoral |
| IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
| JP2000191519A (ja) * | 1998-12-25 | 2000-07-11 | Nippon Kayaku Co Ltd | 薬効成分の不快な官能的性質が隠蔽された速放性粒状物 |
| US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US6663888B2 (en) * | 2001-12-14 | 2003-12-16 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
| JP5062871B2 (ja) * | 2003-05-13 | 2012-10-31 | 東和薬品株式会社 | 苦味を低減した口腔内崩壊錠剤 |
| EP1694305B1 (en) * | 2003-12-01 | 2019-10-16 | Recordati Ireland Limited | Pharmaceutical compositions comprising lercanidipine |
| US8545881B2 (en) * | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| GB0419355D0 (en) | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| US20060165788A1 (en) * | 2004-09-09 | 2006-07-27 | Wattanaporn Abramowitz | Lercanidipine pH dependent pulsatile release compositions |
| US20060165789A1 (en) * | 2004-09-09 | 2006-07-27 | Forest Laboratories, Inc. | Lercanidipine modified release compositions |
| US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| TW200616681A (en) * | 2004-10-05 | 2006-06-01 | Recordati Ireland Ltd | Lercanidipine capsules |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| WO2006047493A2 (en) | 2004-10-21 | 2006-05-04 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| NZ575171A (en) | 2006-08-31 | 2012-04-27 | Aptalis Pharmatech Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
-
2007
- 2007-08-29 NZ NZ575171A patent/NZ575171A/en not_active IP Right Cessation
- 2007-08-29 WO PCT/US2007/077153 patent/WO2008027993A2/en not_active Ceased
- 2007-08-29 US US11/847,219 patent/US20080069878A1/en not_active Abandoned
- 2007-08-29 ES ES07814553T patent/ES2953390T3/es active Active
- 2007-08-29 EP EP07814553.9A patent/EP2056792B1/en active Active
- 2007-08-29 RU RU2009111588/15A patent/RU2434630C2/ru not_active IP Right Cessation
- 2007-08-29 MX MX2009002166A patent/MX2009002166A/es active IP Right Grant
- 2007-08-29 KR KR1020097006605A patent/KR101468053B1/ko not_active Expired - Fee Related
- 2007-08-29 CA CA2661683A patent/CA2661683C/en active Active
- 2007-08-29 MX MX2014009830A patent/MX370905B/es unknown
- 2007-08-29 JP JP2009526896A patent/JP5513113B2/ja not_active Expired - Fee Related
- 2007-08-29 BR BRPI0716196-4A2A patent/BRPI0716196A2/pt not_active IP Right Cessation
- 2007-08-29 KR KR1020147023220A patent/KR20140114887A/ko not_active Ceased
-
2009
- 2009-02-24 IL IL197204A patent/IL197204A0/en unknown
-
2013
- 2013-06-06 US US13/911,961 patent/US10864166B2/en active Active
- 2013-06-10 JP JP2013121984A patent/JP5913207B2/ja active Active
-
2020
- 2020-11-02 US US17/086,862 patent/US12151028B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009111588A (ru) | Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств | |
| JP2020059755A5 (enExample) | ||
| CA2906172C (en) | Rapidly dispersible dosage form of topiramate | |
| JP2017019858A5 (enExample) | ||
| JP5878022B2 (ja) | 抗コリン薬を具える放出制御組成物 | |
| US20170000799A1 (en) | Oral pharmaceutical composition | |
| JP2009502969A5 (enExample) | ||
| PT1830855E (pt) | Formas de apresentação farmacêuticas sólidas, para administração oral, contendo ritaroxaban com libertação modificada | |
| JP2013512250A5 (enExample) | ||
| JP2007119479A5 (enExample) | ||
| WO2010127346A1 (en) | Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics | |
| US10004691B2 (en) | Orally disintegrable tablet | |
| HK1209337A1 (en) | Medicament-containing hollow particle | |
| JP6687624B2 (ja) | 乱用抵抗性医薬組成物 | |
| EP2540318A1 (en) | Sustained-release solid preparation for oral use | |
| JP2012532194A5 (enExample) | ||
| WO2021018414A1 (en) | Pharmaceutical composition comprising dabigatran etexilate | |
| IL293653B1 (en) | A dosage form for use in therapy comprising a core, an intermediate layer, and an enteric coating in a defined ratio | |
| JP5664225B2 (ja) | 不快味マスキング粒子及びこれを含有する経口製剤 | |
| WO2022074681A1 (en) | Pharmaceutical compositions with enhanced blend uniformity and content uniformity | |
| ES2516693T3 (es) | Esferoides farmacéuticos | |
| JP5070618B2 (ja) | 腸溶性顆粒剤及びその製造方法 | |
| JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
| CN105307644A (zh) | 用于减少递送变化性的具有多种剂量单元的美沙拉嗪药物组合物 | |
| WO2013051036A1 (en) | Use of pharmaceutical composition for gastroretentive sustained and pulsatile drug delivery system |